Document:

exv10w1

 

EXHIBIT 10.1

Execution Copy

TERMINATION AGREEMENT

     This Termination Agreement (this “Agreement”) is entered into as of June 6, 2007 (the
“Effective Date”) by and between InterMune, Inc., a Delaware corporation with its principal place
of business at 3280 Bayshore Boulevard, Brisbane, California 94005 (“InterMune”) and Boehringer
Ingelheim Austria GmbH, an Austrian corporation, with its registered office at Dr. Boehringer-Gasse
5-11, A-1121 Vienna, Republic of Austria (“BI Austria”). InterMune and BI Austria may be referred
to herein each individually as a “Party” and jointly as the “Parties.”

RECITALS:

     WHEREAS, InterMune and BI Austria entered into that certain Data Transfer, Clinical Trial and
Market Supply Agreement dated January 27, 2000, as amended by the First Amendment dated June 19,
2002 (“Amendment No. 1”), Amendment No. 2 dated September 18, 2003 (“Amendment No. 2”), Amendment
No. 3 dated July 26, 2005 (“Amendment No. 3”) and Amendment No. 4 dated December 21, 2006
(“Amendment No. 4”) (collectively, the “Original Supply Agreement”), a copy of which is attached
hereto as Exhibit A; and

     WHEREAS, InterMune and BI Austria now desire to (i) terminate the Original Supply Agreement in
its entirety, (ii) enter into a new supply agreement consistent with the parameters set forth in
Exhibit B attached hereto (“New Supply Agreement”) pursuant to which BI Austria shall
manufacture and supply to InterMune and InterMune shall purchase from BI Austria that recombinant
human interferon-gamma 1b product marketed under the trademark “Actimmune®” and (iii) amend, to the
extent necessary, that certain Amended and Restated Quality Agreement dated December 15, 2005
between the Parties (“Quality Agreement”), all upon the terms and conditions contained in this
Agreement.

     NOW, THEREFORE, in consideration of the foregoing recitals which are hereby incorporated by
reference herein and the mutual covenants herein contained, and for good and valuable
consideration, the receipt and sufficiency which are hereby acknowledged, InterMune and BI Austria
hereby agree as follows:

ARTICLE 1 — DEFINITIONS

     Any capitalized term contained herein and not otherwise defined herein shall have the meaning
ascribed to such term in the Original Supply Agreement.

ARTICLE 2 – TERMINATION OF ORIGINAL SUPPLY AGREEMENT

	2.1	 	Termination. The Original Supply Agreement shall be deemed terminated in its entirety
effective as of the effective date of the New Supply Agreement (“Termination Date”). As of
the Termination Date, except as expressly set forth in Section 2.2 of this Agreement, neither
Party shall have any further rights or obligations arising out of or in connection with the
Original Supply Agreement.

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

1

 

	2.2	 	Survival. Notwithstanding the termination of the Original Supply Agreement as set forth
in Section 2.1 above, Sections 9, 10, 11 and 12 of the Original Supply Agreement shall
survive termination of the Original Supply Agreement for the duration of the time period, if
any, set forth therein, with respect to any PRODUCT and BBS manufactured and supplied by BI
Austria to InterMune under the Original Supply Agreement prior to the Termination Date and
CONFIDENTIAL INFORMATION disclosed by a Party to the other Party under the Original Supply
Agreement prior to the Termination Date.

ARTICLE 3 – TERMINATION PAYMENT AND RELEASE

	3.1	 	Termination Payment. In connection with the termination of the Original Supply Agreement and
subject to entry into the New Supply Agreement as provided in Section 4.1 below, InterMune’s
total financial obligation to BI Austria shall be [*] (“Termination Payment”). The
Termination Payment shall be paid as follows:

	 	3.1.1	 	The 2006 Prepayment (defined in Section 3.2 below) shall be applied to
the Termination Payment so that InterMune’s remaining financial obligation shall be
[*] (“Cash Payment”); and
	 
	 	3.1.2	 	The Cash Payment shall be paid by InterMune to BI Austria within [*]
calendar days of the Termination Date and receipt of invoice by InterMune.

	 	 	The Parties acknowledge and agree that the Cash Payment includes [*] and [*] for [*] of [*]
to be delivered by [*]. The balance of the Termination Payment shall compensate BI Austria
for costs incurred in connection with the termination of the Original Supply Agreement.

	3.2	 	Application of 2006 Credit. In connection with Section 3.1.1 above, the Parties hereby agree
that the Three Million Three Hundred Ninety-Four Thousand Fifty Euros
(3,394,050 €) paid by
InterMune to BI Austria pursuant to Amendment No. 4 of the Original Supply Agreement (“2006
Prepayment”) shall be applied against such Termination Payment.

	3.3	 	Release. Effective as of the Termination Date, each Party (the “Releasor”), for itself and
on behalf of its successors-in-interest and permitted assigns, hereby irrevocably releases and
forever discharges the other Party (the “Releasee”) and its successors-in-interest and
permitted assigns, and each of its and their respective Representatives (as defined below),
from any and all losses, obligations, liabilities, claims or responsibilities, of whatever
kind or manner, in each case arising in connection with the Original Supply Agreement, but
specifically excluding any breach of any obligations set forth in this Agreement and those
provisions of the Original Supply Agreement that survive termination as set forth in Section
2.2 of this Agreement. As used herein, “Representatives” means directors, officers,
employees, agents, consultants, advisors, accountants, attorneys and representatives.

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

2

 

	 	 	Each Releasee understands and acknowledges that it may not currently know of losses or
claims or may have underestimated the severity of losses. Part of the consideration provided
by this Agreement was given in exchange for the release of such claims. Each Releasee hereby
waives any rights or benefits under California Civil Code Section 1542 (or any similar
statute in any other jurisdiction), which provides that:

	 	 	 	“A general release does not extend to claims which the creditor does
not know or suspect to exist in his favor at the time of executing
the release, which if known by him must have materially affected his
settlement with debtor.”

ARTICLE 4 – NEW SUPPLY AGREEMENT AND QUALITY AGREEMENT

	4.1	 	Entry into New Supply Agreement. Within thirty (30) days of the Effective Date hereof or any
mutually agreed upon extension, the Parties shall enter into the New Supply Agreement,
consistent with the parameters set forth in Exhibit B attached hereto.

	4.2	 	Quality Agreement. Contemporaneously with the execution of the New Supply Agreement, the
Parties shall enter into the appropriate amendment of the Quality Agreement such that the
Quality Agreement shall, as of the effective date of the New Supply Agreement, apply to the
New Supply Agreement.

ARTICLE 5 – REPRESENTATIONS AND WARRANTIES

	5.1	 	Representations and Warranties of Each Party. Each Party represents and warrants to the
other Party that, as of the Effective Date:

	 	5.1.1	 	it is duly organized, validly existing and in good standing under the
laws of the jurisdiction of incorporation;
	 
	 	5.1.2	 	it has the full right, power and authority to enter into this
Agreement and to perform its obligations hereunder;
	 
	 	5.1.3	 	this Agreement has been duly-executed by it and is legally binding
upon it, enforceable in accordance with its terms (except in all cases as such
enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting the enforcement of creditors’ rights generally
and except that the availability of the equitably remedy of specific performance or
injunctive relief is subject to the discretion of the court or other tribunal
before which any proceeding may be brought); and
	 
	 	5.1.4	 	the execution, delivery and performance of this Agreement by it does
not conflict with any agreement, instrument or understanding, oral or written, to
which it is a party or by which it may be bound, nor violate any material law

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

3

 

	 	 	 	or regulation of any court, governmental body or administrative or other agency
having jurisdiction over it.

ARTICLE 6- MISCELLANEOUS

	6.1	 	Dispute Resolution; Governing Law.

	 	6.1.1	 	In the event of any controversy or claim arising out of, relating to
or in connection with any provision of this Agreement, or the rights or obligations
of the Parties hereunder, the Parties first shall try to settle their differences
amicably between themselves by referring the disputed matter to the Chief Executive
Officer of InterMune and the Chief Executive Officer of BI Austria for discussion
and resolution. Either Party may initiate such informal dispute resolution by
sending written notice of the dispute to the other Party, and within ten (10) days
of such notice the Chief Executive Officer of InterMune and the Chief Executive
Officer of BI Austria shall meet for attempted resolution by good faith
negotiations. If such personnel are unable to resolve such dispute within thirty
(30) days of initiating such negotiations, each Party may thereafter pursue any and
all rights and remedies it may have at law or equity. If mutually agreeable, the
Parties may explore alternative forms of dispute resolution, such as mediation.
	 
	 	6.1.2	 	This Agreement shall be governed by and construed in accordance with
the laws of the place of domicile of the defendant party.
	 
	 	6.1.3	 	The Parties expressly exclude the application of the United Nations
Convention on Contracts for the International Sale of Goods to this Agreement.

	6.2	 	Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a
particular default or other matter shall not constitute a waiver of such Party’s rights to the
future enforcement of its rights under this Agreement, excepting only as to an express written
and signed waiver as to a particular matter for a particular period of time.

	6.3	 	Severability. If any of the provisions of this Agreement or parts thereof should be or
become invalid, the remaining provisions will not be affected. The Parties shall undertake to
replace the invalid provision or parts thereof by a new provision which will approximate as
closely as possible the intent of the Parties.

	6.4	 	Entire Agreement. This Agreement and the Exhibits set forth the entire agreement between the
Parties, and supersede all previous agreements, negotiation and understanding, written or
oral, regarding the subject matter hereof. This Agreement may be modified or amended only by
an instrument in writing duly executed on behalf of the Parties.

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

4

 

	6.5	 	Ambiguities. Ambiguities, if any, in this Agreement shall not be strictly construed against
either Party, regardless of which Party is deemed to have drafted the provision at issue.

	6.6	 	Counterparts. The Agreement may be executed in two or more counterparts, each of which shall
be an original and all of which shall constitute the same document.

	6.7	 	English Language. The English language will govern any interpretation of or dispute in
connection with this Agreement.

[Signature Page Follows]

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

5

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

	 	 	 	 	 	 	 	 	 
	BOEHRINGER INGELHEIM AUSTRIA GMBH	 	 	 	INTERMUNE, INC.
	 
	 	 	 	 	 	 	 	 
	BY:

	 	/s/ Prof. Dr. Rolf G. Werner
	 	 	 	BY:
	 	/s/ Robin Steele
	 

	 	 
	 	 	 	 	 	 
	NAME: Prof. Dr. Rolf G. Werner	 	 	 	NAME: Robin Steele
	 
	TITLE: Senior Vice President, Corporate

Division Biopharmaceuticals	 	 	 	TITLE: Senior Vice President,
General Counsel
	 
	 	 	 	 	 	 	 	 
	BOEHRINGER INGELHEIM AUSTRIA GMBH	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	BY:

	 	/s/ Frank Ternes	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	NAME: Frank Ternes	 	 	 	 	 	 
	 
	TITLE: Senior Vice President, Division
Biopharmaceuticals & Operations	 	 	 	 	 	 

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

6

 

EXHIBITS

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

7

 

Exhibit A

ORIGINAL SUPPLY AGREEMENT, AS AMENDED FROM TIME TO TIME

[as previously filed with the Securities and Exchange Commission]

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

8

 

Exhibit B

NEW SUPPLY AGREEMENT

Form of New Supply Agreement to be negotiated and agreed upon by the Parties in good faith. Such
New Supply Agreement shall address, in addition to other items, the following points:

[*]

 

			
	[*] = 	 	 Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

9exv10w2

 

EXHIBIT 10.2

EXECUTION VERSION

SUPPLY AGREEMENT

     THIS SUPPLY AGREEMENT (the “AGREEMENT”), is made effective as of the 29th day
of June 2007 (the “EFFECTIVE DATE”) by and between InterMune, Inc. (“InterMune”), a California
corporation, having an address at 3280 Bayshore Boulevard, Brisbane, California 94005, USA, and
Boehringer Ingelheim Austria GmbH (“BI Austria”), an Austrian corporation, having its registered
office at Dr. Boehringer-Gassge 5 – 11, A-1121 Vienna, Republic of Austria. InterMune and BI
Austria may be referred to herein each individually as a “Party” and jointly as the “Parties.”

     WHEREAS, InterMune holds an exclusive sublicense under a license from GENENTECH (as
defined herein) to manufacture, use and sell recombinant human gamma-interferon (“INTERFERON GAMMA
1b”, as further described herein) products in the USA and certain other territories, which
INTERFERON GAMMA 1b is approved by the FDA for the indications Chronic Granulomatous Disease and
severe, malignant Osteopetrois, and is sold in the USA under the trade-mark ACTIMMUNE® (the
“GENENTECH PRODUCT”, as further described herein); and

     WHEREAS, Boehringer Ingelheim International GmbH (BII), an affiliate of BI Austria and BI
Pharma KG, holds an exclusive license from GENENTECH to manufacture, use and sell INTERFERON GAMMA
1b in certain other territories, and is the registration-holder for an INTERFERON GAMMA 1b product
in certain countries for the indication Chronic Granulomatous Disease and is sold in Europe under
the trade-mark IMUKIN® (the “BI PRODUCT”, as further described herein); and

     WHEREAS, BI Austria and its affiliate BI Pharma KG (as defined hereinafter) own
facilities specialized for cGMP manufacture of biopharmaceuticals and manufactures and supplies the
BI PRODUCT to BII to meet BII’s needs with respect thereto; and

     WHEREAS, the Parties had entered into that certain Data Transfer, Clinical Trial and Market
Supply Agreement dated the 27th of January 2000, as amended by the First Amendment dated the 19th
of June 2002 (“Amendment No. 1”), Amendment No. 2 dated the 18th of September 2003 (“Amendment No.
2”), Amendment No. 3 dated the 26th of July 2005 (“Amendment No. 3”) and Amendment No. 4 dated the
21st of December 2006 (“Amendment No. 4”) (collectively, the “ORIGINAL SUPPLY AGREEMENT”) pursuant
to which, among other things, (i) BI Austria conducted the activities necessary to show
comparability between the GENENTECH PRODUCT and the BI PRODUCT for BI Austria to be registered with
the FDA as a manufacturer for an INTERFERON GAMMA 1b product to be sold under the ACTIMMUNE®
trade-mark for the US market and other territories controlled by InterMune and (ii) BI Austria
subsequently manufactured and supplied to InterMune finished INTERFERON GAMMA 1b product to meet
InterMune’s needs with respect thereto; and

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

     WHEREAS, the Parties recently entered into that certain Termination Agreement dated
the 6th of June 2007 (“TERMINATION AGREEMENT”) whereby the Parties agreed, among other things, to
terminate the ORIGINAL SUPPLY AGREEMENT and enter into a new supply agreement to replace the
ORIGINAL SUPPLY AGREEMENT; and

     WHEREAS, the Parties wish to enter into this AGREEMENT which shall constitute the
“New Supply Agreement” for purposes of the TERMINATION AGREEMENT and which sets forth the terms and
conditions pursuant to which BI Austria will continue on a going forward basis to manufacture and
supply to InterMune and InterMune will purchase from BI Austria finished INTERFERON GAMMA 1b
product to meet InterMune’s needs with respect thereto.

     NOW, THEREFORE, in consideration of the foregoing recitals which are hereby
incorporated by reference herein and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

1. Definitions

     The following capitalized definitions will apply throughout this Agreement:

1.1 AFFILIATE means (i) any corporation or business entity fifty percent (50 %) or more of the
voting stock of which is and continues to be owned directly or indirectly by any party hereto; (ii)
any corporation or business entity which directly or indirectly owns fifty percent (50 %) or more
of the voting stock of any party hereto; or (iii) any corporation or business entity under the
direct or indirect control of such corporation or business entity as described in (i) or (ii).

1.2 APPROVAL means a regulatory approval required from a HEALTH AUTHORITY in order to manufacture
BBS or PRODUCT for use in clinical trials or market supply as applicable, in the applicable
jurisdiction.

1.3 BI AUSTRIA’S IMPROVEMENTS shall mean all INFORMATION comprising any inventions, modifications
and/or improvements to the INTERMUNE TECHNOLOGY or to the GENENTECH TECHNOLOGY, that BI Austria or
BI Pharma KG conceive of or reduce to practice pursuant to the ORIGINAL SUPPLY AGREEMENT and/or
this AGREEMENT, either individually or in conjunction with one or more third parties or BI
Affiliates, including all patent and patent applications covering any of the foregoing.

1.4 BI AUSTRIA’S TECHNOLOGY means all INFORMATION in the field of manufacturing and testing of
biopharmaceuticals, including without limitation the MANUFACTURING PROCESS but only to the extent
that it relates solely to BI PRODUCT, and including all patents and patent applications
covering any of the foregoing, that are owned or CONTROLLED by BI Austria or BI Pharma KG during
the term of the ORIGINAL SUPPLY AGREEMENT and/or this AGREEMENT and that are related to or useful
in BI Austria’s

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

2

 

carrying out its obligations under this AGREEMENT, but specifically excluding
INTERMUNE’S TECHNOLOGY and BI AUSTRIA’S IMPROVEMENTS.

1.5 BII means Boehringer Ingelheim International GmbH, an AFFILIATE of BI Austria GmbH and BI
Pharma KG.

1.6 BI PHARMA KG means BI Austria’s AFFILIATE BI Pharma KG, FRG-88397 Biberach an der Riss,
Birkendorfer Straße 65, Germany, owning an FDA inspected and cGMP-certified facility.

1.7 BI PRODUCT means the liquid formulation of INTERFERON GAMMA 1b approved in various countries
for which BII has acquired rights from GENENTECH for the treatment of Chronic Granulomatous
Disease, and manufactured by BI Austria and BI Pharma KG for sale in Europe under the trademark
IMUKIN®.

1.8 BLA means a Biologics License Application, as defined by the regulations promulgated under the
FD&C ACT, and any equivalent application with respective HEALTH AUTHORITIES.

1.9 BULK BIOLOGICAL SUBSTANCE (BBS) means a bulk form of the PRODUCT. This bulk form is the [*].

1.10 BULK SPECIFICATIONS mean the specifications for BBS listed in Exhibit 1.

1.11 cGMP means the current Good Manufacturing Practices of all applicable HEALTH AUTHORITIES,
including without limitation the FDA, and including without limitation all applicable rules,
regulations, guides and guidance, such as 21C.F.R. parts 210 and 211 and parts 600 and 610.

1.12 CMC means the Chemistry, Manufacturing, and Controls content of a submission to a HEALTH
AUTHORITY.

1.13 COA means a Certificate of Analysis, a document listing testing parameters, specifications and
test results (in a format and detail as listed in Exhibit 2).

1.14 COC means a Certificate of Compliance confirming compliance with cGMP regulations and signed
by BI Austria’s authorized Qualified Person, the Head of Production and the Head of Quality
Assurance (in a format and such detail as listed in Exhibit 3).

1.15 CONFIDENTIAL INFORMATION means any proprietary INFORMATION (a) disclosed by one Party to the
other from and after the Effective Date hereof, or (b) developed by either Party pursuant to this
AGREEMENT, except for INFORMATION which (i) is already in the public domain at the time of its
disclosure to the receiving Party; (ii) becomes part of the

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

3

 

public domain through no wrongful
action or omission of the receiving Party after disclosure to the receiving Party; (iii) is already
known to the receiving Party at the time of disclosure as evidenced by the receiving Party’s
written records; or (iv) is independently developed by the receiving Party without the use or
application of the disclosing Party’s proprietary information.

1.16 CONTROLLED means, with respect to any material, INFORMATION or intellectual property right,
possession of the ability by a Party to grant access, a license, or a sublicense to such material,
INFORMATION or intellectual property right as provided for herein without violating an agreement
with a Third Party as of the time such Party would be first required hereunder to grant the other
Party such access, license or sublicense.

1.17 EURO means a euro, which is the European unit of currency.

1.18 FDA means the United States Food and Drug Administration and any successor agency thereto.

1.19 FD&C ACT means the United States Food, Drug & Cosmetic Act as amended from time to time and
any supplements thereunder, and any equivalent regulation of any HEALTH AUTHORITIES.

1.20 FINAL RELEASE means the release of PRODUCT by InterMune or its licensees for clinical trial
use or market supply, as applicable.

1.21 GENENTECH means Genetech, Inc. with its principle place of business at 1 DNA Way, South San
Francisco, CA, 94080-4990.

1.22 GENENTECH PRODUCT means the formulation of INTERFERON GAMMA 1b which was manufactured in the
US by GENENTECH for sale under the trademark ACTIMMUNE and approved by the FDA for the treatment of
Chronic Granulomatous Disease and Osteopetrosis.

1.23 GENENTECH TECHNOLOGY means all INFORMATION relating to the manufacture, use or sale of
INTERFERON GAMMA 1b that is licensed to either Party pursuant to an agreement with GENENTECH,
including without limitation the MANUFACTURING PROCESS, and all patents and patent applications
covering such INFORMATION.

1.24 HEALTH AUTHORITIES mean all regulatory authorities having jurisdiction over the manufacture,
use and/or sale of the PRODUCT in the TERRITORY, including but not limited to the FDA.

1.25 INFORMATION means (a) techniques, data, inventions, practices, methods, knowledge, know-how,
skill, experience, test data (including pharmacological, toxicological and clinical test data),
analytical and quality control data, regulatory submissions, correspondence

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

4

 

and communications,
marketing, pricing, distribution, cost, sales, manufacturing, patent and legal data or
descriptions, compositions of matter, assays and biological materials, and (b) all intellectual
property rights in and to any of the foregoing.

1.26 INTERFERON-GAMMA l b means the recombinant human Interferon-Gamma 1b derived from a [*], and
that is the active ingredient in ACTIMMUNEÒ. The relevant amino acid sequence is set forth in
Exhibit 4.

1.27 INTERMUNE’S TECHNOLOGY means all INFORMATION that is CONTROLLED by INTERMUNE during the term
of the ORIGINAL SUPPLY AGREEMENT and/or the term of this AGREEMENT that is related to or useful in
BI Austria’s manufacture of PRODUCT hereunder, and all patents and patent applications covering any
of the foregoing; provided that “INTERMUNE’S TECHNOLOGY” shall not include any INFORMATION (i)
owned or CONTROLLED by BI Austria prior to the Effective Date, (ii) conceived of, or reduced to
practice or acquired by BI Austria outside the ORIGINAL SUPPLY AGREEMENT during the term thereof or
outside this AGREEMENT during the term hereof, or (iii) the GENENTECH TECHNOLOGY.

1.28 MCB means the original Master Cell Bank derived from the [*] and established by GENENTECH.

1.29 MANUFACTURER’S RELEASE means the release of the PRODUCT by BI Austria to InterMune or its
designee.

1.30 MANUFACTURING PROCESS means the process for fermentation, purification, filling, labeling and
packaging of BBS and PRODUCT, as described in Exhibit 5.

1.31 MATERIAL SUPPLY BREACH means a failure of BI Austria: (a) to supply to InterMune at least [*]
of InterMune’s binding forecasted requirements of PRODUCT (or actual orders, if less) that are due
for delivery by the designated delivery date during the then-current calendar quarter; or (b) to
repeatedly [*] materially violate against cGMP, as described in Sections 5.6 and 5.7.

1.32 ORIGINAL SUPPLY AGREEMENT has the meaning ascribed to it in the recitals of this AGREEMENT.

1.33 PRODUCT shall mean a finished product consisting of formulated INTERFERON GAMMA 1b filled into
the designated containers for clinical supply and for market supply, as described in Exhibit 6, or
shall mean a finished product of formulation buffer filled into the designated containers for
clinical supply (placebo).

1.34 PROJECT MANAGER means the responsible person designated by each Party to be responsible for
the communication of all information concerning this AGREEMENT. As of the

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

5

 

Effective Date, the
person designated as InterMune’s PROJECT MANAGER and the person designated as BI Austria’s PROJECT
MANAGER are listed in Exhibit 7. Either Party may change its own designated PROJECT MANAGER by
providing written notice thereof to the other Party.

1.35 PRODUCT SPECIFICATIONS mean the specifications for the PRODUCT as set forth in Exhibit 8, or
as otherwise agreed by the Parties in writing.

1.36 PROJECT TEAM means the team as listed in Exhibit 7 and described in Section 6.1.

1.37 QUALITY AGREEMENT means that Amended and Restated Quality Agreement dated the 15th
of December 2005 between the Parties.

1.38 QUALITY ASSURANCE REQUIREMENTS mean those requirements set forth in the QUALITY AGREEMENT.

1.39 STEERING COMMITTEE means the committee as listed in Exhibit 9 and as further described in
Section 6.2.

1.40 TERMINATION AGREEMENT has the meaning ascribed to it in the recitals of this AGREEMENT.

1.41 TERRITORY means the US, Japan and all additional territories, including but not limited to
Canada, as to which InterMune has or may acquire the right to manufacture, use or sell INTERFERON
GAMMA 1b products during the term of this AGREEMENT.

1.42 US means the United States of America.

2. General 

2.1 InterMune’s Tasks and Responsibilities

     2.1.1 Support

     InterMune shall timely send all documentation, and otherwise timely provide all information
and other assistance, reasonably requested by BI Austria for use under this AGREEMENT. InterMune
shall provide such reasonable technical support at its own expense, which support shall include
access to InterMune’s expert personnel upon reasonable notice and at such reasonable times as the
Parties may agree.

     2.1.2 Contact with Health Authorities

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

6

 

          2.1.2.1 InterMune, as the license holder for the GENENTECH PRODUCT in the US, shall have the
overall responsibility regarding all contacts with the HEALTH AUTHORITIES and shall be solely
responsible for filing all regulatory documents required by any HEALTH AUTHORITIES. BI Austria
shall support InterMune in all matters regarding the manufacturing and quality control of PRODUCT
as reasonably requested by InterMune, but InterMune shall be the leading Party, responsible for
co-ordination of all regulatory matters.

          2.1.2.2 InterMune will notify BI Austria in due time, but in no event later than five (5)
business days in advance of any meeting with any HEALTH AUTHORITIES with regard to manufacture,
supply and quality control of the PRODUCT manufactured by BI Austria or BI Pharma KG under this
AGREEMENT. BI Austria shall have the right to participate in such meetings with such HEALTH
AUTHORITIES during the portion of such meetings relating to BI Austria’s or BI Pharma KG’s
manufacture, supply and quality control of the PRODUCT.

          2.1.2.3 BI Austria will be responsible for drawing up the annual report required by the HEALTH
AUTHORITIES reasonably in advance of the due date, and will be responsible of matters regarding the
manufacture of PRODUCT. InterMune shall submit such report to the HEALTH AUTHORITIES and shall
provide BI Austria with a copy of the finally submitted report.

     2.1.3 Shipment of Material by InterMune

     Any materials, e.g. samples, sent by InterMune (or by a third party on behalf of InterMune) to
BI Austria shall be made by shipment from InterMune’s facility (or the third party’s facility, as
the case may be) to BI Austria’s facility in Vienna. Shipping costs including insurance will be
borne by InterMune, and risk of loss in transit shall lie with InterMune.

2.2 BI Austria’s Tasks and Responsibilities

     2.2.1 Regulatory Support

          2.2.1.1 BI Austria agrees to co-operate with InterMune in obtaining and maintaining all US
governmental approvals and registrations relevant to the CMC section of the registration dossier
(and their foreign equivalents) as requested by InterMune.

          2.2.1.2 The Parties shall consult with each other concerning the scope and content of all
regulatory filings, and shall jointly define the requirements for the necessary PRODUCT
registration with the FDA so that BI Austria shall be able to fulfill its obligations under this
AGREEMENT with respect to the CMC portion of such PRODUCT registration. With respect to any part
of the CMC portion which contain BI Austria and/or BI Pharma KG INFORMATION, BI Austria shall be
provided an opportunity to review and comment on such parts prior to submission to a HEALTH
AUTHORITY as set forth in the QUALITY AGREEMENT.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

7

 

     2.2.2 Format and Content of Documents

     BI Austria’s Quality Management System demands a special format for certain documents (i.e.
batch records, testing procedures, technical reports) which is binding. For those documents where a
binding format is not obligatory the Parties shall agree in writing on a master format. With
respect to the dates contained in these documents, and in particular in all reports and when dates
occur in connection with signatures, the European writing style shall apply. The order shall be as
follows: dd / mm / yy (day/month/year).

     2.2.3 [*] Production at [*] Versus [*]

     The Parties acknowledge and agree that as of the Effective Date hereof, BI Austria had
developed a [*] process for production of BBS at [*] and has commenced production of BBS for
InterMune at such a scale. The Parties have agreed that it is feasible to [*] to a [*] yield
process for production of BBS at [*] given the [*] market demand of PRODUCT. As result, BI Austria
shall, at its sole cost and expense, take all steps necessary to [*] the MANUFACTURING PROCESS to a
[*] and to obtain any and all necessary process validation and APPROVALS for such [*] MANUFACTURING
PROCESS. Upon receipt of the necessary process validation and APPROVALS for such scaled-down
MANUFACTURING PROCESS, the Parties shall amend Exhibit 5 attached hereto to reflect the [*]
process. During the process of obtaining the necessary process validation and APPROVALS for such
[*] MANUFACTURING PROCESS, should a HEALTH AUTHORITY request additional certain PRODUCT-specific
studies specifically for the PRODUCT to be supplied to InterMune and no HEALTH AUTHORITY requests
such similar additional studies for the BI PRODUCT, InterMune shall bear the respective costs of
such additional studies. In the event a HEALTH AUTHORITY requests additional studies for PRODUCT
and the BI PRODUCT the Parties shall negotiate in good faith on sharing the cost for such studies.

3. Manufacture and Supply

3.1 General

     3.1.1 BI Austria shall [*] supply to InterMune BBS or PRODUCT for the treatment or prevention
of any human disease or condition, except for the treatment or prevention of any type of cardiac or
cardiovascular disease or condition. [*] BBS or PRODUCT for the treatment of any human disease or
condition, except for the treatment or prevention of any type of cardiac or cardiovascular
condition, [*]. InterMune shall [*] purchase from BI Austria, all of [*] for the term of this
AGREEMENT, subject to Section 3.7. This provision does not in any way restrict [*].

     3.1.2 All BBS manufactured by BI Austria hereunder, and all PRODUCT manufactured and supplied
to InterMune by BI Austria hereunder, shall be manufactured and supplied in

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

8

 

accordance with the BBS
SPECIFICATIONS and PRODUCT SPECIFICATIONS, the cGMP requirements, the QUALITY ASSURANCE
REQUIREMENTS as set forth in the QUALITY AGREEMENT and all applicable laws, regulations and
ordinances of the jurisdiction in which such manufacture occurs.

     3.1.3 BI Austria shall manufacture BBS according to the BULK SPECIFICATIONS. BI Austria shall
manufacture PRODUCT according to PRODUCT SPECIFICATIONS for clinical supply and for market supply.
BBS for clinical and market supply shall be manufactured at BI Austria and transferred to BI Pharma
KG for vialing, labeling (but only for market supply) and packaging. Manufacturing and filling of
vials, labeling (but only for market supply) as well as the packaging and storing of PRODUCT shall
be in accordance with the PRODUCT SPECIFICATIONS, the cGMP requirements, the QUALITY ASSURANCE
REQUIREMENTS as set forth in the QUALITY AGREEMENT and all applicable laws, regulations and
ordinances of the jurisdiction in which such manufacturing and/or filling occurs. Notwithstanding
the fact that BI Austria takes BI Pharma KG as a toll manufacturer for filling, labeling (for
market supply) and packaging of PRODUCT, BI Austria takes responsibility for the manufacture and supply of
PRODUCT to InterMune in accordance with the terms and conditions of this AGREEMENT.

3.2 Forecasts

     3.2.1 Beginning with [*], unless otherwise agreed by the Parties, InterMune shall provide a
rolling forecast for the next [*]. The first [*] of such forecast shall be firm (red zone). [*]
shall be referred to as the blue zone. For [*] InterMune can reduce its forecast by [*] percent but
only [*] in each [*], and may increase its forecast by [*] percent, but only [*] in each [*]. For
[*] InterMune can reduce its forecast by [*] percent but only [*] in each [*], and may increase its
forecast by [*] percent, but only [*] in each [*]. [*] will constitute a non-binding forecast
(green zone). After the first forecast has been submitted by InterMune to BI Austria, successive
forecasts shall be submitted on a [*] basis at the latest on every first day of every [*].
InterMune agrees to order the PRODUCT in filling lot quantities or multiples thereof (available lot
sizes are 25.000 vials, or any other then available lot sizes). For purposes of clarity, the
rolling forecast to be provided by InterMune under this Section 3.2 shall include the [*] vials
that constitute the initial order of PRODUCTS described in Section 3.4 below.

     3.2.2 If InterMune requires more PRODUCT than is set forth in the current firm forecast, BI
Austria shall use commercially reasonable efforts in good faith to supply InterMune with PRODUCT as
requested; provided that for the amounts of PRODUCT in excess of such forecast which BI Austria is
unable to supply, despite such commercially reasonable efforts, InterMune may use a secondary
source manufacturer in accordance with the procedures set forth in Section 3.7.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

9

 

     3.2.3 If InterMune reduces the forecast for [*] and [*] by an amount in excess of [*] percent
(net of any increases in actual orders for these [*], then InterMune shall be [*] which was [*] in
excess of the [*] percent reduction at the rate of [*] percent of the unit price of the PRODUCT
then in effect. Similarly, if InterMune reduces the forecast for [*] by an amount in excess of [*]
percent (net of any increases in actual orders for these [*], then InterMune shall be obligated to
pay for PRODUCT which was not ordered in excess of the [*] percent reduction at the rate of [*]
percent of the unit price of the PRODUCT then in effect.

3.3 Purchase Orders

     3.3.1 InterMune shall be obligated to purchase amounts of PRODUCT under this Agreement
consistent with the binding/nonbinding rolling forecast set forth in Section 3.2 above. When
purchasing PRODUCT hereunder, InterMune shall submit written purchase orders to BI Austria. To the
extent that the terms of a purchase order or of BI Austria’s or BI Pharma KG’s “GENERAL CONDITIONS
OF SALE” are inconsistent with the terms of this AGREEMENT, this AGREEMENT shall prevail.

     3.3.2 BI Austria shall guarantee that at the date of FINAL RELEASE all PRODUCT supplied to
InterMune shall have a minimum residual shelf life of not less than [*] of PRODUCT shelf life,
provided that InterMune shall strictly fulfill its contractual timelines regarding FINAL RELEASE as
set forth in Sections 3.5 and 5.3.

     3.3.3 Subject to Section 3.4, BI Austria shall ship all PRODUCT as set forth in Section 3.5 by
the date and in the quantities specified in the applicable purchase order. BI Austria shall be
obligated to accept any purchase order within the range of permitted variation in the forecasted
quantities as set forth in Section 3.2.1. and 3.2.2. Any other purchase order shall be binding on
BI Austria only if it is accepted by BI Austria, which acceptance shall not be unreasonably
withheld. If BI Austria does not accept such a purchase order, then InterMune may use a secondary
source manufacturer for such purchase order in accordance with the procedures set forth in Section
3.7.

     3.3.4 InterMune shall be obligated to buy and BI Austria shall be obligated to sell only the
quantities of PRODUCT which are subject to a purchase order accepted by BI Austria; provided that
BI Austria shall accept sufficient purchase orders from InterMune annually to meet its obligations
pursuant to Section 3.6.2 and in accordance with the rolling forecast model pursuant to Section
3.2.1. Any purchase order (or portion thereof) for which InterMune has not received a written
rejection from BI Austria within thirty (30) business days of BI Austria’s receipt of such purchase
order shall be deemed accepted by BI Austria. With respect to PRODUCTS ordered by InterMune for its
clinical supply requirements, the number of vials supplied by BI Austria shall not exceed the
number of vials subject to the applicable purchase order submitted by InterMune; provided, however,
that if the number of vials BI Austria is able to supply falls below the number of vials ordered by
InterMune in such purchase order and such

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

10

 

lesser number is within a reasonable range of the number
ordered by InterMune, BI Austria shall notify InterMune in writing and inquire as to whether such
lesser number of vials is acceptable and if not, whether BI Austria should produce an additional
batch of BBS to produce enough vials to satisfy InterMune’s purchase order. If InterMune notifies
BI Austria that such lesser number of vials is acceptable to InterMune, then the applicable
purchase order shall be deemed to be amended to provide for such lesser number of vials and BI
Austria shall be deemed to have accepted such purchase order in accordance with Section 3.3. On
the other hand, if InterMune notifies BI Austria that BI Austria should manufacture an additional
batch of BBS to produce the number of vials ordered by InterMune in its purchase order submitted to
BI Austria, then BI Austria shall be obligated to produce the additional batch of BBS, InterMune
shall be obligated to purchase any excess vials of PRODUCT produced by BI Austria from such
additional batch of BBS and the purchase order submitted to BI Austria by InterMune shall be deemed
amended to account for any excess vials resulting from the additional batch of BBS and such
purchase order shall be deemed accepted by BI Austria in accordance with Section 3.3.

3.4 Initial Order

     The Parties acknowledge and agree that as of the Effective Date hereto, (i) InterMune has
submitted to BI Austria and BI Austria has accepted a one-time purchase order for [*] vials of
PRODUCT to be manufactured and delivered by BI Austria to InterMune in accordance with this
AGREEMENT in the [*], and (ii) with respect to such [*] vials of PRODUCT, [*] set forth in the [*].

3.5 Shipment of Product and Material by BI Austria

     3.5.1 The PRODUCT and all material (e.g. samples) shall be shipped [*] either BI Pharma KG,
FRG 88397 Biberach an der Riss, Germany or BI Austria’s facility in Vienna, Austria, as the case
may be, to InterMune or as directed by InterMune, in accordance with Incoterms 2000 as published by
the International Chamber of Commerce. InterMune’s designated carrier shall be used to ship PRODUCT
to the site designated by InterMune. The Parties acknowledge and agree that the only deviation from
the definition of [*] is that [*] shall be responsible and bear the cost of [*] the DRUG PRODUCT
onto the [*] designated carrier such that [*] from BI Austria to InterMune only [*]. Risk of loss
in transit by InterMune’s designated contract carrier shall lie with InterMune, except where such
loss is caused by BI Austria’s or BI Pharma KG’s negligence.

     3.5.2 BI Austria will provide or will have provided assistance to InterMune regarding
necessary procedures for exportation and/or importation of PRODUCT.

3.6 Testing and Rejection

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

11

 

     3.6.1 Within [*] business days of its receipt of PRODUCT at such destination as may be
designated by InterMune, InterMune may perform such tests and samplings as are appropriate to
determine whether such PRODUCT meets the applicable PRODUCT SPECIFICATIONS. If InterMune refuses
acceptance of PRODUCT, then InterMune shall inform BI Austria in writing within [*] further
business days of any aspect in which such PRODUCT fails to conform to the PRODUCT SPECIFICATIONS.
If BI Austria does not receive such a notice within [*] business days of InterMune’s receipt of
such PRODUCT, then InterMune shall be deemed to have accepted the PRODUCT; provided that InterMune
shall have the right to revoke its acceptance of such goods if it later discovers latent defects
not reasonably discoverable at the time of receipt.

     3.6.2 If BI Austria receives a notice from InterMune pursuant to Section 3.5.1 that InterMune
does not accept any PRODUCT supplied hereunder, then BI Austria shall immediately start re-testing
the PRODUCT using the retained samples in order to evaluate process issues and other reasons for
such non-compliance.

     3.6.3 Regardless of whether BI Austria agrees with InterMune’s rejection of such PRODUCT, if
requested in writing by InterMune, BI Austria shall use reasonable efforts to
promptly replace such allegedly defective PRODUCT, the costs of which shall be borne as set
forth in Section 3.6.4.

     3.6.4 In the event that BI Austria’s re-testing does not verify InterMune’s reasons for
rejecting such PRODUCT and InterMune is convinced by BI Austria and agrees with BI Austria that
InterMune’s reasons for rejecting such PRODUCT are unjustified , InterMune shall pay BI Austria
reasonable internal and external costs for conducting such re-testing; provided, however, that, if
InterMune is not convinced and does not agree that InterMune’s reasons for rejecting such PRODUCT
are unjustified, the Parties shall mutually agree on an independent laboratory that shall determine
by applying validated product-specific analytical methods whether such PRODUCT meets the PRODUCT
SPECIFICATIONS. The conclusions of this independent laboratory shall be binding upon both Parties.
If such laboratory determines that such PRODUCT does meet the PRODUCT SPECIFICATIONS, then
InterMune shall bear the costs for such independent laboratory and for any replacement PRODUCT
manufactured and supplied to InterMune by BI Austria pursuant to Section 3.6.3. If such laboratory
determines that such PRODUCT does not meet the PRODUCT SPECIFICATIONS, then BI Austria shall bear
the costs for such independent laboratory and for any such replacement of PRODUCT.

     3.6.5 Neither Party may destroy any PRODUCT alleged not to meet the PRODUCT SPECIFICATIONS
until the independent laboratory determines whether such PRODUCT meets the applicable PRODUCT
SPECIFICATIONS and provides written notification to the Parties with respect to such determination,
unless BI Austria accepts InterMune’s basis for such rejection. Thereafter, BI Austria shall have
the obligation to destroy or have destroyed, at its cost, all such rejected PRODUCT. Upon BI
Austria’s written request and at BI Austria’s cost,

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

12

 

InterMune shall either destroy or return to BI
Austria any rejected PRODUCT. The Parties agree that in the event of destruction of PRODUCT, the
method of such destruction shall be in compliance with all applicable laws, rules and regulations.

     3.6.6 Claims on account of quantity, loss or damages to PRODUCT (other than claims that such
PRODUCT does not meet the PRODUCT SPECIFICATIONS and latent defects not reasonably detectable upon
inspection) will be dispatched by InterMune in writing within ten (10) business days following
receipt thereof. BI Austria shall use reasonable efforts to replace the quantity of goods which
such claims apply, which replacement shall be at InterMune’s expense unless such claims are due to
the negligence of BI Austria.

3.7 Second Source Manufacturer

     3.7.1 BI Austria acknowledges that it is critical that InterMune be ensured continuity of
supply of PRODUCT for use in clinical trials and market supply. BI Austria shall ensure continuity
of supply of PRODUCT for use in clinical trials and market supply. Nevertheless, due to the
potentially growing market demand of PRODUCT, BI Austria’s ability to manufacture and supply
PRODUCT shall be carefully observed. Should at any time BI Austria have any indication
that continuity of supply can not be ensured, BI Austria shall immediately inform InterMune
thereof in writing. In this event the matter would be immediately forwarded to the STEERING
COMMITTEE to discuss second source manufacture of PRODUCT reasonably and in good faith.

     3.7.2 In the event the STEERING COMMITTEE decides that it is appropriate for InterMune to
establish a second source manufacturer, InterMune agrees to provide the first opportunity to
qualify as a second source manufacturer for PRODUCT to a BI Austria AFFILIATE. If such an AFFILIATE
is – as foreseeable — unable to supply InterMune’s PRODUCT requirements then InterMune shall be
free to choose an alternate supplier. In this case BI Austria shall assist InterMune in
transferring the MANUFACTURING PROCESS to a third party supplier by providing reasonable technical
assistance and documentation as necessary for a transfer to a party well skilled in the manufacture
of such biotech products at InterMune’s cost.

     3.7.3 In addition, the parties, through the STEERING COMMITTEE shall work together in good
faith to develop a risk mitigation plan to minimize any risk of interruption in the supply of
PRODUCT for use in clinical trials and market supply, which plan may include, among other things,
production of excess PRODUCT or materials relating thereto (e.g., BBS) that can be used as a buffer
and/or the off-site storage of certain PRODUCT or materials relating thereto.

3.8 Material Supply Breach

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

13

 

     3.8.1 In the event of a MATERIAL SUPPLY BREACH, InterMune shall provide BI Austria written
notification of such MATERIAL SUPPLY BREACH. Upon BI Austria’s receipt of such notice and failure
to cure such MATERIAL SUPPLY BREACH within the timetable and activity plan agreed upon the Parties
to cure such MATERIAL SUPPLY BREACH, InterMune shall have the right to purchase from a second
source manufacturer, to be agreed upon within the STEERING COMMITTEE in accordance with Section
3.7, such amounts of PRODUCT as necessary to offset BI Austria’s shortfall in fulfilling
InterMune’s purchase orders for such PRODUCT (or the anticipated shortfall, in the event of
repeated [*] material violation against cGMP).

     In the event, that

     (i) BI Austria AFFILIATE can not qualify as a second source manufacturer for PRODUCT or

     (ii) in the event such a BI Austria AFFILIATE is – as foreseeable — unable to supply
InterMune’s PRODUCT requirements and

     (iii) provided that PRODUCT supply as requested by InterMune by a different second source
manufacturer, a company experienced in manufacturing of biopharmaceuticals derived from [*], and
selected by InterMune could demonstrably take place earlier than a MATERIAL
SUPPLY BREACH by BI Austria could be remedied, BI Austria shall assist InterMune as requested
in transferring the MANUFACTURING PROCESS to such a second source supplier, to be selected by
InterMune by providing reasonable technical assistance and documentation relating to the
manufacture, testing and supply of BBS and the PRODUCT as necessary at BI Austria’s cost. Such
second source manufacturer would bear responsibility for putting the MANUFACTURING PROCESS in
place. The total financial commitment for reasonable technical assistance shall not exceed the [*]
for the period of [*].

     3.8.2 In the event that BI Austria reasonably anticipates that there is a substantial
likelihood that a MATERIAL SUPPLY BREACH will occur, BI Austria shall promptly notify InterMune in
writing thereof. Upon receipt of such notice, the Parties shall promptly confer to discuss the
circumstances and magnitude of such potential MATERIAL SUPPLY BREACH, and to determine in good
faith whether there are any reasonable steps that BI Austria could take to avoid such MATERIAL
SUPPLY BREACH. If InterMune is not reasonably satisfied that BI Austria will be able to avoid such
MATERIAL SUPPLY BREACH, then InterMune shall forward this issue to the STEERING COMMITTEE to
determine whether it is necessary or desirable to establish a second source manufacturer in
accordance with Section 3.7.

4. Prices and Payment

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

14

 

4.1 The prices to be paid by InterMune for the PRODUCT provided hereunder have been agreed to by
the Parties. Initially, the price of PRODUCT for market supply shall be [*] for a unit of [*]
vials of PRODUCT and the price of one single vial of PRODUCT for clinical supply shall be [*]
(placebo [*]). Commencing [*], the price for the PRODUCT will be adjusted year by year in
accordance with [*]. (By way of example, [*]. The price for 2005 will increase at [*].).
Payments by InterMune to BI Austria under this AGREEMENT shall be in EUROS.

4.2 BI Austria will be entitled [*] prices [*] to BI Austria of [*] which are [*] PRODUCT at the
time [*]. InterMune shall be entitled to have any [*] selected by InterMune and acceptable to BI
Austria which [*] only. BI Austria shall provide InterMune with [*] days’ notice of any [*].

4.3 The price for PRODUCT or any services agreed by the Parties shall be paid to BI Austria no
later than [*] days after the date that BI Austria’s invoice is received by InterMune. Payment of
the invoice amounts shall be made in Austria, [*], into an account with such Austrian credit
institution as shall be notified by BI Austria to InterMune from time to time.

4.4 All payments owed to BI Austria by InterMune on the basis of accounts rendered shall be made in
such a way that [*] shall be [*] that are [*] invoice amounts (e.g. [*]). In the event of a default
in payment for whatever reason, default interest at a rate of [*] p.a. shall be payable on the
outstanding amount due. BI Austria reserves the right to claim any damage exceeding such amount
that shall have been caused by such delay, subject to Section 11.1.

4.5 [*] owed to BI Austria by InterMune for the initial order of [*] vials of PRODUCT described in
Section 3.4 above.

5. Quality Assurance and compliance with law

5.1 Manufacturer’s Release of Product

     5.1.1 BI Austria shall be responsible for the MANUFACTURER’S RELEASE of PRODUCT according to
the PRODUCT SPECIFICATIONS, the cGMP requirements, the QUALITY ASSURANCE REQUIREMENTS as set forth
in the QUALITY AGREEMENT and all applicable Austrian and German laws. BI Austria shall certify in
writing that each shipment lot of PRODUCT was produced and tested in compliance with (i) the
SPECIFICATIONS, (ii) the cGMP requirements (iii) QUALITY ASSURANCE REQUIREMENTS and (iv) all
applicable laws, regulations and ordinances of the jurisdiction in which such manufacture occurs.

     5.1.2 BI Austria shall provide to InterMune, through BI Pharma KG, QUALITY ASSURANCE
REQUIREMENTS as set forth in the QUALITY AGREEMENT including but not limited to a COA and COC
signed by the appropriate personnel as defined in BI Austria’s Quality Management System for each
shipment lot of PRODUCT from BI Pharma KG’s manufacture site in Biberach, Germany, in order to
prove BI Austria’s compliance with the Article 5.1.1.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

15

 

5.2 Storage of Records and Batch Samples

     5.2.1 BI Austria shall maintain in compliance with cGMP standards all batch samples and all
records required by law or as otherwise mutually agreed in writing by the Parties (i.e. batch
records, analytical raw data) necessary to evidence compliance with all its obligations under this
AGREEMENT and relating to the manufacture of the BBS and of PRODUCT. The documentation concerning
manufacture of BBS shall be stored at BI Austria and concerning manufacture of PRODUCT shall be
stored in Biberach. Storage of retained samples of BBS as well as PRODUCT shall be at BI Austria or
BI Pharma KG, as applicable.

     5.2.2 Copies of all documentation and information relating to the manufacture, processing,
packaging and shipping of, BBS, PRODUCT and/or required to support InterMune’s BLA or other
regulatory submissions, including but not limited to information relating to batch records,
methods, equipment and the facility, will be provided by BI Austria to InterMune for review and
inclusion as necessary in InterMune’s regulatory submissions.

     5.2.3 All such samples and records shall be maintained for a period not less than five (5)
years from the date of expiration of each batch of PRODUCT to which such samples and records
pertain, or such longer period as may be required by local law and the rules or regulations of the
FDA or other applicable HEALTH AUTHORITIES. Following the expiration of such required retention
period, prior to the destruction of any such sample or record, BI Austria shall give written notice
thereof to InterMune, and InterMune shall have the right to request, receive and retain such
samples and records with no further compensation to BI Austria.

5.3 Final Release

     FINAL RELEASE of PRODUCT supplied by BI Austria and/or BI Pharma KG hereunder for use in
humans shall solely be made by and under the responsibility of InterMune.

5.4 Third Party Services

     Except as specifically provided for herein, BI Austria will not contract out to any third
party the manufacture and testing of BBS or PRODUCT, without prior written approval from InterMune,
which shall not be unreasonably withheld.

5.5 Consent to Changes

     BI Austria will not make any changes to BI Austria’s, and shall ensure that BI Pharma KG shall
not make any changes to BI Pharma KG’s, respective manufacturing facilities, equipment, testing
procedures, validation, suppliers of raw materials and components or documentation systems that are
solely related to the BBS or PRODUCT and having a non-trivial impact on the BBS or PRODUCT, without
the prior written consent of InterMune and solely as is permitted by cGMP. In the event that a
supplier of raw material is unable to deliver the

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

16

 

respective raw material in time for scheduled
manufacturing BI Austria is free to choose another supplier, provided that such supplier supplies
such raw material that fully meets the respective raw material specification, and subject to BI
Austria’s providing InterMune prior written notice thereof.

5.6 Inspections by Health Authorities

     5.6.1 BI Austria shall secure that during any inspections at BI Austria’s and/or BI Pharma
KG’s facilities by any applicable HEALTH AUTHORITIES, BI Austria shall give InterMune prior written
notice thereof promptly following BI Austria’s receipt of notice of such inspection, so that
representatives of InterMune may attend and participate in such inspections, for example, to answer
PRODUCT and any clinical trial related questions.

     5.6.2 BI Austria shall advise, and shall ensure that BI Pharma KG shall advise, InterMune in
writing immediately of any requests by any applicable HEALTH AUTHORITIES
for inspections at either of BI Austria’s or BI Pharma KG’s facilities, but in any event, no
later than ten (10) business days prior to the scheduled date of such inspection. Upon reasonable
notice, InterMune or its representatives may attend only such portions of such inspections or
audits that deal with PRODUCT related issues, due to BI Austria’s other secrecy obligations. Access
to such facilities may be subject to reasonable restrictions customarily placed upon visitors to
the site.

     5.6.3 BI Austria also agrees to notify InterMune within [*] business days of any written or
oral inquiries, notifications, or inspection activity by any HEALTH AUTHORITIES (or any third party
authorized by the HEALTH AUTHORITIES) in regard to PRODUCT. BI Austria shall provide a reasonable
description to InterMune of any such inquiries, notifications or inspections promptly (but in no
event later than [*] business days) after such visit or inquiry. BI Austria shall furnish to
InterMune (a) within [*] business days after receipt, any report or correspondence issued by the
HEALTH AUTHORITIES (or a third party authorized by a HEALTH AUTHORITIES) in connection with such
visit or inquiry, including but not limited to, any FDA Form 483 (List of Inspectional
Observations) or warning letter, and (b) not later than five (5) business days prior to the time it
provides to a HEALTH AUTHORITY, copies of any and all proposed written responses or explanations
relating to items set forth above (each, a “Proposed Response”), in each case purged only of trade
secrets or other confidential or proprietary information of BI Austria that are unrelated to its
obligations under this AGREEMENT or are unrelated to PRODUCT. BI Austria shall discuss with
InterMune any comments provided by InterMune on the Proposed Response; provided that InterMune
shall have the final decision with respect to those portions of the final written response or
explanation to be provided to the HEALTH AUTHORITIES that relate to PRODUCT manufactured hereunder.
After the filing of a response with the appropriate HEALTH AUTHORITIES, BI Austria will notify
InterMune of any further contacts with the HEALTH AUTHORITIES relating to BI Austria’s manufacture
of PRODUCT hereunder.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

17

 

     5.6.4 BI Austria shall promptly correct, and shall ensure that BI Pharma KG shall promptly
correct, any facility-related violations or deficiencies promptly at its own expense. Equipment,
system and process-related violations or deficiencies that are solely PRODUCT-related shall be
corrected promptly by BI Austria or BI Pharma KG, respectively, at InterMune’s cost.

     In the event such corrections will not only be necessary for PRODUCT but as well for BI
PRODUCT the appropriate allocation of the related costs between the Parties shall be determined by
the PROJECT TEAM.

5.7 Audits by InterMune

     5.7.1 InterMune shall have the right to inspect and audit both of BI Austria’s and BI Pharma
KG’s manufacturing facilities and records for regulatory compliance. These audits shall
occur annually upon reasonable notice, and more frequently for good and reasonable cause. BI
Austria shall respond in writing to InterMune regarding any items of non-compliance with cGMP
identified by InterMune during such audits, whether with respect to the BI Austria or the BI Pharma
KG facility, within [*] business days of InterMune’s notice thereof, and without delay remedy any
such agreed upon items of non-compliance with cGMP.

     5.7.2 If BI Austria can not remedy such non-compliance, whether with respect to the BI Austria
or the BI Pharma KG facility, within [*] business days of notice thereof BI Austria’s response
shall include a written plan and timetable including reasonable timelines. Considering the fact
that BI Austria is dependent on certain third parties to supply services to it, BI Austria shall
use best efforts to assign such timelines to these third parties accordingly in order to meet all
timelines for such remedy. Such plan and timetable shall be subject to InterMune’s approval, which
shall not unreasonably be withheld. In the event that BI Austria does not respond with a plan and
timetable as described above within such [*] day period, or InterMune does not approve such
proposed plan and timetable for good reason, the issue shall be forwarded to the STEERING COMMITTEE
for resolution. In the event InterMune approves such plan and timetable, but BI Austria fails to
remedy such non-compliance in accordance with such plan and timetable, then InterMune shall have
the right to terminate this AGREEMENT pursuant to Section 13.2.1.

5.8 Manufacturing Facilities

     BI Austria represents and warrants that it and BI Pharma KG shall obtain all relevant
APPROVALS required by the relevant HEALTH AUTHORITIES for each of their respective manufacturing
facilities and that each of their respective manufacturing facilities conform, and will during the
term of this AGREEMENT conform, to the cGMP.

5.9 Compliance with Law

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

18

 

     5.9.1 BI Austria shall comply, and shall ensure that its subcontractor BI Pharma KG shall
comply with, all local applicable rules, laws and regulations (including without limitation cGMP)
in performing its obligations under this AGREEMENT. InterMune shall comply with all applicable
rules, laws and regulations in performing its obligations under this AGREEMENT.

     5.9.2 All costs in connection with maintaining BI Austria’s and BI Pharma KG’s compliance with
all applicable local regulatory requirements and cGMP in performing under this AGREEMENT, including
but not limited to the maintenance and upgrading of all technical facilities and infrastructure and
the training of personnel, shall be borne by BI Austria. BI Austria shall obtain and maintain, and
shall ensure that BI Pharma KG obtains and maintains, all permits and licenses necessary to its
performance under this AGREEMENT at their own expense. All costs in connection with any
requirements by InterMune or a HEALTH AUTHORITY which
relate specifically and solely to the PRODUCT (and not also to the BI PRODUCT) shall be solely
borne by InterMune.

5.10 Environmental

     BI Austria shall, and shall ensure that BI Pharma KG shall, properly dispose of any and all
hazardous waste materials involved with the manufacture of BBS and PRODUCT that are generated or
resulting from the activities performed hereunder, if any, in full compliance with all applicable
local laws and regulations at BI Austria’s sole liability and expense.

5.11 Quality Agreement

     The Parties hereby agree that the QUALITY AGREEMENT is hereby incorporated by reference herein
and that it shall apply in full force to BBS and PRODUCT produced under this AGREEMENT. In the
event of any conflict between this AGREEMENT and the QUALITY AGREEMENT, this AGREEMENT shall govern
to the extent of such conflict except to the limited extent that a provision of the QUALITY
AGREEMENT expressly and specifically states an intent to supersede.

6. Co-operation and co-ordination between the Parties

6.1 Project Team

     6.1.1 The day-to-day responsibilities of the Parties with respect to this AGREEMENT shall be
overseen by the PROJECT TEAM, which shall be responsible for deciding operational and scientific
issues arising out of this AGREEMENT and unanimously agreeing in good faith with respect to the
monitoring of the compliance with this AGREEMENT.

     6.1.2 The PROJECT TEAM shall consist of a team consisting of equal numbers of people, if
feasible, each appointed by InterMune and BI Austria and notified to the other, which appointees
may be changed from time to time by the appointing Party on written notice to the

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

19

 

other Party. Each
member of the PROJECT TEAM shall be a person of appropriate skill and experience. Either Party may
change its own designated PROJECT TEAM members provided, however that the total number of members
of the PROJECT TEAM may not be changed if feasible, nor the number of members representing
InterMune decreased, without the Parties’ prior written agreement. InterMune’s and BI Austria’s
respective members of the PROJECT TEAM as of the Effective Date are listed in Exhibit 7.

     6.1.3 During the term of this AGREEMENT, the PROJECT TEAM shall meet regularly to communicate
updates and provide a forum for decision-making and rapid resolution of issues arising under this
AGREEMENT. Meetings of the PROJECT TEAM may be conducted by
telephone conference, videoconference or face-to-face meetings as agreed by the PROJECT TEAM,
provided that the PROJECT TEAM shall meet at least once a year in a face-to-face meeting at a
mutually agreed location.

     6.1.4 Decisions of the PROJECT TEAM shall be reflected in the approved minutes. Meeting
minutes shall be prepared jointly by the PROJECT MANAGERS to record all issues discussed and
decisions. Minutes that have not been objected to in writing by a Party within six (6) business
days of receipt thereof shall be deemed approved by such Party and followed by issuance of two (2)
copies of the minutes duly executed by the Parties’ PROJECT MANAGER.

     6.1.5 In the event that the PROJECT TEAM is unable to reach agreement on any issue and is
unable to make decisions arising out of operational and scientific issues within ten (10) business
days, each Party may call in an expert of its own choice to render advice to the PROJECT TEAM.
Based on the advice of such expert(s) and the team members’ know-how, the PROJECT TEAM will try to
resolve such issue. In the event that the PROJECT TEAM fails to reach agreement on an issue within
thirty (30) business days of first undertaking resolution of such issue, such issue shall then be
referred to the STEERING COMMITTEE for immediate resolution.

6.2 Steering Committee

     6.2.1 The Parties shall create a STEERING COMMITTEE consisting of the PROJECT MANAGER of each
Party and authorized representatives who shall be appointed by InterMune and by BI Austria in equal
numbers, if feasible, and notified to the other Party. The STEERING COMMITTEE shall be responsible
for unanimously agreeing in good faith all issues on which the PROJECT TEAM has been unable to
reach agreement and, where possible, make decisions arising out of such issues as well as carry out
the specific functions, including but not limited to decisions with an impact on costs and
timelines of any activities to be carried out under this AGREEMENT. Each Party may change its own
designated STEERING COMMITTEE members by providing written notice thereof to the other Party;
provided, however that the total number of members of the STEERING COMMITTEE may not be changed, if
feasible, nor the number of

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

20

 

members representing InterMune decreased, without the Parties’ prior
written agreement. The members of the STEERING COMMITTEE are listed in Exhibit 9.

     6.2.2 The STEERING COMMITTEE shall attempt in good faith to expeditiously and fairly resolve
all issues before it. In the event that the STEERING COMMITTEE is unable to resolve any issue
before it within fifteen (15) business days from the date that such issue is referred to it, such
issue shall be referred to the Chief Executive Officer of InterMune and the Chief Executive Officer
of BI Austria for prompt, good faith resolution. If such individuals do not reach agreement on such
issue within fifteen (15) days of such referral, then each Party shall be free to pursue all
available legal and/or equitable remedies.

6.3 Limitation of Powers

     The powers of the PROJECT TEAM and the STEERING COMMITTEE are limited to those expressly set
forth in this AGREEMENT. Without limiting the generality of the foregoing, neither the PROJECT TEAM
nor the STEERING COMMITTEE shall have the right to amend this AGREEMENT. The actions of the PROJECT
TEAM and/or the STEERING COMMITTEE shall not substitute for either Party’s ability to exercise any
right, nor excuse the performance of any obligation, set forth herein.

7. intellectual Property and Licenses

7.1 The ownership of INTERMUNE’S TECHNOLOGY and shall remain with InterMune and shall not vest in
BI Austria.

7.2 The ownership of BI AUSTRIA’S TECHNOLOGY shall remain with BI Austria and shall not vest in
InterMune.

7.3 BI Austria shall retain ownership of BI AUSTRIA’S IMPROVEMENTS. BI Austria hereby grants to
InterMune a non exclusive, perpetual, sublicenseable, [*] license under BI AUSTRIA’S IMPROVEMENTS
(i) to the extent necessary to develop, use, import, offer for sale and sell products containing
INTERFERON GAMMA 1b in the name and on the account of InterMune in the TERRITORY, and (ii) in the
event InterMune transfer the process to a second source manufacturer as permitted under this
AGREEMENT, to make and have made products containing INTERFERON GAMMA 1b in the name and on account
of InterMune in the TERRITORY, whereby in each case InterMune shall assume the costs to be paid by
BI Austria for awards to inventors of BI AUSTRIA’S IMPROVEMENTS, as such awards are set forth in
written agreements between BI Austria and such inventor or in an applicable industry labor contract
or mandatory by Austrian laws.

7.4 The Parties shall each have an undivided one-half ownership interest in any INFORMATION jointly
conceived of or reduced to practice by the Parties pursuant to the ORIGINAL SUPPLY AGREEMENT and/or
this AGREEMENT (“JOINT INFORMATION”).

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

21

 

InterMune shall [*] of any JOINT INFORMATION that comprises
(a) any regulatory filing (or documentation and raw data relating thereto) relating to PRODUCT
manufactured hereunder or the ORIGINAL SUPPLY AGREEMENT, or (b) any manufacturing documentation
(including without limitation batch records) relating to PRODUCT manufactured hereunder or the
ORIGINAL SUPPLY AGREEMENT (“PRODUCT INFORMATION”). Upon request by InterMune, without additional
consideration, BI Austria agrees to promptly execute documents, testify and take other acts at
InterMune’s expense as InterMune may deem necessary or desirable to procure, maintain, perfect, and
enforce the full benefits, enjoyment, rights, title and interest of the PRODUCT INFORMATION, on a
worldwide basis. In the event InterMune is unable for any
reason, after reasonable effort, to secure BI Austria’s signature on any document needed in
connection with the actions specified in this Section 7.4, BI Austria hereby irrevocably designates
and appoints InterMune and its duly authorized officers and agents as its agent and attorney in
fact, which appointment is coupled with an interest, to act for and in its behalf to execute,
verify and file any such documents and to do all other lawfully permitted acts to further the
purposes of this Section 7.4 with the same legal force and effect as if executed by BI Austria.

7.5 InterMune hereby grants to BI Austria (with the right to sublicense solely to BI Pharma KG) a
non-exclusive, nontransferable license to use INTERMUNE’S TECHNOLOGY solely for the purpose of
manufacturing PRODUCT for InterMune, as provided in this AGREEMENT. The license granted under this
Section shall automatically terminate upon the expiration or termination of this AGREEMENT.

7.6 New Indications

     7.6.1 In the event that InterMune receives approval in the TERRITORY to commercially sell
PRODUCT for indications other than Chronic Granulomatous Disease and severe, malignant
Osteopetrosis, and provided that InterMune has the right to grant a license to BII in the BI
TERRITORY to make, use and sell PRODUCT for such additional indications (a “NEW INDICATIONS
LICENSE”), InterMune shall provide BII written notice thereof.

     7.6.2 BII shall notify InterMune in writing within thirty (30) days of InterMune’s notice (the
“NOTIFICATION PERIOD”) whether BII desires to obtain a NEW INDICATIONS LICENSE. If InterMune does
not receive written notice from BII during the NOTIFICATION PERIOD that BII desires to obtain a NEW
INDICATIONS LICENSE, then InterMune shall have no further obligations under this Section 7.6. If
InterMune does receive written notice from BII that BII desires to obtain a NEW INDICATIONS
LICENSE, then BII and InterMune shall engage in good faith negotiations for sixty (60) business
days thereafter regarding the reasonable commercial terms upon which InterMune would be willing to
grant such a license. If at the end of such sixty (60) business day period, BII and InterMune have
not entered into a written agreement under which InterMune grants a NEW INDICATIONS LICENSE to BII,
then InterMune shall have no further obligation under this Section 7.6.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

22

 

8. Complaints; Adverse Events; Recalls

8.1 InterMune shall inform BI Austria of any complaints, adverse reaction reports, safety issues or
toxicity issues relating to any PRODUCT of which it becomes aware, regardless of the origin of such
information, within the time frame required by cGMP but in no event later than two (2) days from
the initial complaint or report.

     8.1.1 InterMune shall retain and manage complaints in accordance with cGMP. The Parties hereby
agree to cooperate with one another and with any HEALTH AUTHORITY in the evaluation and
investigation of any complaint, claim or adverse reaction report related to the manufacture of such
PRODUCT with the intention of complying with cGMP.

     8.1.2 If any such event occurs, BI Austria shall retain any unused supplies of such PRODUCT
and its associated components, and all associated batch and other production records in such manner
as InterMune may reasonably direct, and at InterMune’s expense, except to the extent such event is
caused by BI Austria’s wrongful act or omission. BI Austria agrees to respond to InterMune in
respect to such complaint investigations involving BI Austria’s manufacturing of a PRODUCT
hereunder as soon as reasonably possible but in any case within thirty (30) days from receipt by BI
Austria of the report of such complaint and sample (if available), or in the case of a serious
adverse event, within ten (10) days from receipt of the report of such complaint and sample (if
available). InterMune and/or its designee shall serve as the sole point of contact with the FDA or
other applicable HEALTH AUTHORITY concerning any complaints, adverse reaction reports, safety
issues or toxicity issues with respect to PRODUCT.

8.2 If either Party becomes aware at any time of any defect or the possibility of any defect
associated with any PRODUCT manufactured by BI Austria hereunder, such Party will notify the other
Party immediately and confirm the notification as soon as possible in writing.

8.3 InterMune shall notify BI Austria promptly if any PRODUCT manufactured by BI Austria hereunder
is the subject of a recall, market withdrawal or correction, and InterMune and/or its designee
shall have the sole responsibility for the handling and disposition of such recall, market
withdrawal or correction. In the event that a recall is required in connection with BI Austria’s
breach of any of its warranties set forth in Section 9.2 hereof, BI Austria shall reimburse
InterMune for the purchase price of such PRODUCT and all other reasonable costs and expenses
associated with such PRODUCT recall, market withdrawal or correction, but only to the extent that
the foregoing costs and expenses are attributable to BI Austria’s breach of its warranties
hereunder. In all other events of a recall, all costs and expenses incurred in connection with
such PRODUCT recall shall be borne by InterMune. InterMune and/or its designee shall serve as the
sole point of contact with the FDA or other applicable HEALTH AUTHORITY concerning any recall,
market withdrawal or correction with respect to the PRODUCT.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

23

 

8.4 Insurance

     During the term of this AGREEMENT, the Parties shall maintain product liability insurance in
such amounts and with such scope of coverage as are adequate to cover the Parties’ obligations
under this AGREEMENT and as appropriate for companies of like size, taking into account the scope
of activities contemplated herein. Notwithstanding the foregoing the Parties shall maintain minimum
limits of liability of [*] US$  per occurrence and in the aggregate annually. The Parties shall
provide to each other within ten ( 10) business days of execution of this
AGREEMENT and thereafter, once a year upon the other Party’s request, a certificate of
insurance evidencing the respective Party’s product liability insurance. In addition to the
foregoing coverage, the Parties shall maintain Comprehensive General Liability Insurance for limits
of not less than [*] US$ combined single limit for bodily injury and broad form property damage.

9. Representations And Warranties

9.1 Each Party hereby represents and warrants to the other Party that: (a) the person executing
this AGREEMENT is authorized to execute this AGREEMENT; (b) this AGREEMENT is legal and valid and
the obligations binding upon such Party are enforceable by their terms; and (c) the execution,
delivery and performance of this AGREEMENT does not conflict with any agreement, instrument or
understanding, oral or written, to which such Party may be bound, nor violate any law or regulation
of any court, governmental body or administrative or other agency having jurisdiction over it.

9.2 BI Austria represents and warrants that:

     9.2.1 All BBS manufactured hereunder shall conform to BULK SPECIFICATIONS;

     9.2.2 All PRODUCT manufactured and supplied hereunder shall – at the date of shipment -
conform to the PRODUCT SPECIFICATIONS;

     9.2.3 All BBS and PRODUCT manufactured and supplied hereunder shall be manufactured in
accordance with the MANUFACTURING PROCESS;

     9.2.4 All BBS and PRODUCT manufactured hereunder shall be manufactured, handled, stored,
labeled, packaged and transported (from BI Austria to BI Pharma KG) in accordance with the cGMP
requirements, the QUALITY ASSURANCE REQUIREMENTS as set forth in the QUALITY AGREEMENT and all
applicable laws, regulations and ordinances of the jurisdiction in which such manufacture occurs.

     9.2.5 No PRODUCT manufactured and supplied to InterMune hereunder shall be (i) adulterated or
misbranded by BI Austria within the meaning of the FD&C Act, or (ii) an article

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

24

 

that may not be
introduced into interstate commerce under the provisions of Sections 404 or 505 of the FD&C Act;
and

     9.2.6 BI Austria shall not use and shall secure that BI Pharma KG shall not use in any
capacity the services of any persons debarred under 21 U.S.C. sections 335 (a) and 335 (b) in
connection with the manufacture of the PRODUCT under this AGREEMENT.

9.3 Except as expressly provided for herein, BI Austria makes no further warranties of the
merchantability or fitness of the PRODUCT or any warranties of any other nature, express or
implied.

10. Indemnification

10.1 Subject to Section 10.3, BI Austria shall indemnify, defend and hold harmless InterMune and
its officers, directors, employees and agents from and against all third party costs, claims,
(including death and bodily injury) suits, expenses (including reasonable attorneys’ fees),
liabilities and damages (collectively, “LIABILITIES”) arising out of or resulting from any willful
or negligent act or omission by BI Austria or BI Pharma KG relating to the subject matter of this
AGREEMENT, or any defect in the manufacture or any failure to deliver PRODUCT in accordance with BI
Austria’s warranties (except to the extent such LIABILITIES arose or resulted from any negligent
act or omission by InterMune).

10.2 Subject to Section 10.3, InterMune shall indemnify, defend and hold harmless BI Austria and
its officers, directors, employees and agents from and against all LIABILITIES arising out of or
resulting from any willful or negligent act or omission by InterMune relating to the subject matter
of this AGREEMENT, or the use by or administration to any person of a PRODUCT that arises out of
this AGREEMENT (except to the extent such LIABILITIES arose or resulted from any negligent act or
omission by BI Austria or BI Pharma KG or any defect in the manufacture of PRODUCT or any failure
to deliver PRODUCT in accordance with BI Austria’s warranties).

10.3 A Party and its directors, officers, employees and agents which intends to claim
indemnification under this Article 10 (each, an “INDEMNITEE”) shall promptly notify the other Party
(the “INDEMNITOR”) in writing of any action, claim or other matter in respect of which the
INDEMNITEE intend to claim such indemnification; provided, however, that the failure to provide
such notice within a reasonable period of time shall not relieve the INDEMNITOR of any of its
obligations hereunder except to the extent that the INDEMNITOR is prejudiced by such failure. The
INDEMNITEE shall permit the INDEMNITOR at its discretion to settle any such action, claim or other
matter, and the INDEMNITEE agrees to the complete control of such defense or settlement by the
INDEMNITOR. Notwithstanding the foregoing, the INDEMNITOR shall not enter into any settlement that
would adversely affect the INDEMNITEE’s rights hereunder, or impose any obligations on the
INDEMNITEE in addition to those set forth herein in order for it to exercise such rights, without
INDEMNITEE’s prior

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

25

 

written consent, which shall not be unreasonably withheld or delayed. No such
action, claim or other matter shall be settled without the prior written consent of the INDEMNITOR,
which shall not be unreasonably withheld or delayed. The INDEMNITOR shall not be responsible for
any attorneys’ fees or other costs incurred other than as provided herein. The INDEMNITEE shall
cooperate fully with the INDEMNITOR and its legal representatives in the investigation and defense
of any action, claim or other matter covered by the indemnification obligations of this Article 10.
The INDEMNITEE shall have the right, but not the obligation, to be represented in such defense by counsel of its
own selection and at its own expense.

11. Limitations On Liability

11.1 In no event shall either Party be liable to the other Party for any consequential, incidental,
special or indirect damages arising in connection with this AGREEMENT except in the case of willful
misconduct or omission by such Party.

11.2 Except as set forth in the following sentence, BI Austria’s total liability under this
Agreement shall not exceed [*]. However, with respect to BI Austria’s indemnification obligations
under Article 10, BI Austria’s total liability shall not exceed [*] Euros per occurrence of an act
or omission by BI Austria giving rise to a claim for indemnification by InterMune against BI
Austria under Article 10, except in the event of BI Austria’s gross negligence or willful
misconduct.

12. Confidentiality

12.1 Each Party shall treat confidentially all CONFIDENTIAL INFORMATION of the other Party, and
shall not use or disclose such CONFIDENTIAL INFORMATION other than it is expressly permitted under
this AGREEMENT. Each Party will take steps to protect the other Party’s CONFIDENTIAL INFORMATION
that are at least as stringent as the steps such Party uses to protect its own CONFIDENTIAL
INFORMATION, but in no event shall be less than reasonable. Each Party may disclose the other
Party’s CONFIDENTIAL INFORMATION to employees, contractors and agents who are bound by written
obligations of confidentiality and non-use consistent with those set forth in this AGREEMENT. BI
Austria may disclose CONFIDENTIAL INFORMATION for corporate reporting purposes to its AFFILIATES BI
Pharma KG and Boehringer Ingelheim GmbH.

12.2 Each Party may disclose Confidential Information of the other Party hereunder to the extent
that such disclosure is reasonably necessary for prosecuting or defending litigation, complying
with applicable government regulations, conducting preclinical or clinical trials or obtaining
marketing approval for the PRODUCT, provided that if a Party is required by law or regulation to
make any such disclosure of the other Party’s CONFIDENTIAL INFORMATION it will, except where
impracticable for necessary disclosures, for example in the event of medical emergency, give
reasonable advance notice to the other Party of such disclosure requirement and

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

26

 

will use its best
efforts assist such other Party to secure a protective order or confidential treatment of such
CONFIDENTIAL INFORMATION required to be disclosed.

12.3 Neither Party shall disclose CONFIDENTIAL INFORMATION of the other Party in any patent filings
without the prior written consent of such other Party.

12.4 The Parties agree that, except as may otherwise be required by applicable laws, regulations,
rules, or orders, including without limitation the rules and regulations promulgated by the US
Securities and Exchange Commission, and except as may be authorized in Section 12.2, no material
information concerning this AGREEMENT and the transactions contemplated herein shall be made public
by either Party without the prior written consent of the other. The Parties agree that the public
announcement of the execution of this AGREEMENT shall be by one or more press releases mutually
agreed to by the Parties. A failure of a Party to return a draft of a press release with its
proposed amendments or modifications to such press release to the other Party within five (5)
business days of such Party’s receipt of such press release shall be deemed as such Party’s
approval of such press release as received by such Party. Each Party agrees that it shall cooperate
fully and in a timely manner with the other with respect to all disclosures to the Securities and
Exchange Commission and any other governmental and regulatory agencies, including requests for
confidential treatment of CONFIDENTIAL INFORMATION of either Party included in any such disclosure.

12.5 This confidentiality obligations of this Article 12 shall survive the termination or
expiration of this AGREEMENT for a period of five (5) years.

13. Duration and Termination

13.1 Duration

     The AGREEMENT shall be effective as of the Effective Date and shall continue in force until
December 31, 2012. No later than [*] prior to the expiration of this AGREEMENT, the Parties shall
discuss and determine whether the term of the AGREEMENT shall be extended by the Parties. In the
event the Parties mutually determine that the term of the AGREEMENT should be extended, the Parties
shall enter into an amendment to this AGREEMENT to effectuate such an extension.

13.2 Early Termination

     13.2.1 In the event that a Party materially breaches its obligations under this AGREEMENT
(including without limitation a MATERIAL SUPPLY BREACH), the non-breaching Party may terminate this
AGREEMENT upon thirty (30) days prior written notice to the breaching Party, unless the breaching
Party cures such breach to the non-breaching Party’s reasonable satisfaction during such thirty day
period. Notwithstanding the preceding sentence, in the event that a Party materially breaches its
obligations under this AGREEMENT more than

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

27

 

two (2) times in any consecutive twenty-four (24) month
period, the non-breaching Party may terminate this AGREEMENT immediately without providing the
breaching Party an opportunity to cure such breach, by giving the breaching Party written notice
thereof.

     13.2.2 Each Party may terminate this AGREEMENT by notice in writing to the other Party, for
cause, if such other Party is adjudicated to be insolvent or files a petition in bankruptcy.

     13.2.3 InterMune may immediately terminate this AGREEMENT by notice in writing if InterMune
should be prevented by the HEALTH AUTHORITIES from distributing PRODUCT on the market for all
indications. In such event, [*] for the following: (A) InterMune shall either (at InterMune’s
discretion) (i) [*] in accordance with the then existing [*] under the [*] (in which case [*] to
InterMune) or (ii) [*] of the unit price of the PRODUCT then in effect for the PRODUCT forecasted
in the then existing [*] under the [*]; and (B) InterMune [*] any non-cancelable costs incurred by
BI Austria for equipment dedicated to the PRODUCT which equipment was purchased by BI Austria at
InterMune’s request to the extent that InterMune has not yet paid for such equipment; provided that
InterMune shall have no liability to BI Austria under this Section 13.2.3 in the event that such
HEALTH AUTHORITY action is solely due to any breach of BI Austria’s warranties under this Agreement
or any negligence or willful misconduct by BI Austria or BI Pharma KG.

     13.2.4 Either Party may terminate this AGREEMENT upon [*] months written notice in the event
that the other Party assigns this AGREEMENT pursuant to Section 14.3.

     13.2.5 All payments in connection with early termination shall be due within thirty (30) days
after receipt by BI Austria of the notice of early termination from InterMune and receipt by
InterMune of the respective invoice from BI Austria.

13.3 Effect of Termination

     13.3.1 In the event of any termination of this AGREEMENT (other than for BI Austria’s material
breach or negligence or willful misconduct by BI Austria or BI Pharma KG), InterMune shall also do
one of the following (at InterMune’s option): (i) InterMune shall purchase (in which case BI
Austria shall sell) PRODUCT forecasted for [*] (i.e., [*]) and for [*] (i.e., [*) of the then
existing forecast or (ii) InterMune shall pay to BI Austria an amount equal to [*] of the unit
price of the PRODUCT then in effect for the PRODUCT forecasted [*]; provided, however, that with
regard to any [*] by BI Austria (or BI Pharma KG, as the case may be) at the time of termination,
[*] PRODUCT at [*]. Notwithstanding the foregoing, in the event of termination by InterMune under
Section 13.2.3, Section 13.2.3 shall govern rather than this Section 13.3.1.

     13.3.2 In the event of any termination or expiration of this AGREEMENT, at the request of
InterMune, BI Austria shall either (i) destroy all material, including but not limited to samples

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

28

 

and all documentation received from InterMune under this AGREEMENT and under the ORIGINAL SUPPLY
AGREEMENT, or (ii) deliver the same to InterMune or a party nominated by InterMune, at InterMune’s
cost (except in the case of termination by InterMune for BI Austria’s material breach, in which
case such destruction or delivery shall be at BI Austria’s expense).

     13.3.3 BI Austria shall promptly return all of InterMune’s CONFIDENTIAL INFORMATION (as well
as all CONFIDENTIAL INFORMATION of InterMune provided to BI Austria under the ORIGINAL SUPPLY
AGREEMENT) to InterMune, except for a single copy and/or sample of each item for documentation
purposes only. BI Austria’s responsibility to keep and store all other materials provided by
InterMune in the course of this AGREEMENT shall terminate six (6) months after expiration or
termination of this AGREEMENT (except as otherwise provided in Section 5.2).

     13.3.4 InterMune shall promptly return all of BI Austria’s CONFIDENTIAL INFORMATION (as well
as all CONFIDENTIAL INFORMATION of BI Austria provided to InterMune under the ORIGINAL SUPPLY
AGREEMENT) to BI Austria, except for a single copy and/or sample for documentation purposes only.

     13.3.5 The following provisions shall survive termination of this AGREEMENT: Sections 3.8.1,
5.2.3, 7.1, 7.2, 7.3, 7.4, 7.5, 8, 10, 11, 12, 13.2.3, 13.2.5, 13.3 and 14. Termination of this
AGREEMENT shall not relieve either Party of any liability which accrued hereunder prior to the
effective date of such termination, nor preclude either Party from pursuing all rights and remedies
it may have hereunder or at law or in equity with respect to any breach of this AGREEMENT, nor
prejudice either Party’s right to obtain performance of any obligation.

14. Miscellaneous

14.1 Performance by Affiliates

     The Parties recognize that each Party may perform some or all of its obligations under this
AGREEMENT through one or more of its AFFILIATES, provided, however, that each Party shall remain
responsible for such performance by its AFFILIATES and shall cause its AFFILIATES to comply with
the provisions of this AGREEMENT in connection with such performance. Each Party hereby expressly
waives any requirement that the other Party exhaust any right, power or remedy, or proceed against
an AFFILIATE, for any obligation or performance hereunder prior to proceeding directly against such
Party.

14.2 Force Majeure

     Neither Party shall be liable for any failure or delay in performance or non-performance
caused by circumstances beyond the reasonable control of such Party, including but not limited to
acts of God, explosion, fire, flood, labor strike or labor disturbances, sabotage, order or decree

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

29

 

of any court or action of any governmental authority (except where such order, decree or action is
a direct result of BI Austria’s breach of its obligations hereunder), or other causes, whether
similar or dissimilar to those specified which cannot reasonably be controlled by the Party who
failed to perform (each such event, a “FORCE MAJEURE EVENT”). A Party affected by a FORCE MAJEURE
EVENT shall give notice of such to the other Party as soon as is reasonably possible,
and shall resume performance hereunder as soon as is reasonably possible. Each Party shall
have the right to terminate this AGREEMENT in the event that a FORCE MAJEURE EVENT continues for
more than thirty (30) business days upon written notice thereof.

14.3 Assignment

     14.3.1 Except as expressly provided for herein neither this AGREEMENT nor any rights or
obligations hereunder may be assigned by either Party except to an AFFILIATE of either one of the
Parties without the prior written consent of the other Party which shall not be unreasonably
withheld or delayed. Any subsequent assignee or transferee shall be bound by the terms of this
AGREEMENT. Any assignment of this AGREEMENT that is not in conformance with this Section 14.3 shall
be null, void and of no legal effect.

     14.3.2 Notwithstanding the foregoing, InterMune shall have the right to assign this AGREEMENT
in case of a merger, acquisition or sale of substantially all of its assets that relate to this
AGREEMENT after due written notification of BI Austria. In the event the InterMune assignee is a
direct competitor of BI Austria in the field of contract manufacturing of biopharmaceuticals by
means of microbial or yeast fermentation, any document reviews or site inspections (e.g. annual
audit) by such assignee as permitted under this AGREEMENT must only be exercised by an independent
third party consultant agreed upon between the Parties such that the assignee will not have direct
access to BI Austria’s CONFIDENTIAL INFORMATION and such independent third party’s disclosure of BI
Austria’s CONFIDENTIAL INFORMATION to such assignee will be limited to the full extent possible in
order to protect BI Austria’s CONFIDENTIAL INFORMATION.

     14.3.3 In the event that either Party assigns this AGREEMENT as permitted under this Section,
the other Party shall have the right to terminate this AGREEMENT upon [*] months written notice.
InterMune shall not have the right to terminate this AGREEMENT under this Section 14.3.3 (i) in the
event of assignment of the Agreement by BI Austria to an AFFILIATE existing on the Effective Date
in accordance with Section 14.3.1, or (ii) in the event BI Austria assigns the Agreement to an
AFFILIATE not in existence on the Effective Date and such assignment would have no impact on the
day-to-day operations of BI Austria such that the same facility in [*] would continue to perform
its manufacturing obligations under this Agreement.

14.4 Notices

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

30

 

     Any notice required or permitted to be given hereunder by either Party shall be in writing and
shall be (i) delivered personally, (ii) sent by registered mail, return receipt requested, postage
prepaid or (iii) delivered by facsimile and confirmed by certified or registered mail to the
addresses or facsimile numbers set forth below:

	 	 	 
	If to InterMune:

	 	InterMune, Inc.

3280 Bayshore Boulevard

Brisbane, CA 94005 USA

Facsimile: +1 – 415 – 466 – 2300

Attention:
	 
	 	 
	With a copy to:

	 	InterMune, Inc.

3280 Bayshore Boulevard

Brisbane, CA 94005 USA

Facsimile: +1 – 415 – 466 – 2300

Attention: General Counsel
	 
	 	 
	If to BI Austria:

	 	Boehringer Ingelheim Austria GmbH

Dr. Boehringer-Gasse 5 – 11

A-1121 Vienna, Republic of Austria

Facsimile: +43 – 1 – 801 05 – 2440

Attention: Monika Henninger

Customer Relations & Projects
	 
	 	 
	with a copy to:

	 	Boehringer Ingelheim GmbH

Binger Strasse 173

D-55 216 Ingelheim am Rhein

Facsimile: +49 – 61 32 77 – 98 287

Attention: Rolf G. Werner

Corporate Division Biopharmaceuticals

14.5 Dispute Resolution; Governing Law

     14.5.1 In the event of any controversy or claim arising out of, relating to or in connection
with any provision of this AGREEMENT, or the rights or obligations of the Parties hereunder, the
Parties first shall try to settle their differences amicably between themselves by referring the
disputed matter to the Chief Executive Officer of InterMune and the Chief Executive Officer of BI
Austria for discussion and resolution. Either Party may initiate such informal dispute resolution
by sending written notice of the dispute to the other Party, and within ten (10) days of such
notice the Chief Executive Officer of InterMune and the Chief Executive Officer of BI Austria shall
meet for attempted resolution by good faith negotiations. If such personnel are

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

31

 

unable to resolve
such dispute within thirty (30) days of initiating such negotiations, the controversy or claim will
be referred to binding arbitration as set forth in Section 14.5.2.

     14.5.2 Any controversy or claim arising out of, relating to or in connection with any
provision of this AGREEMENT, or the rights or obligations of the Parties hereunder, and not
resolved by executive mediation in accordance with Section 14.5.1 hereof, shall be referred to and
finally settled by binding arbitration, in accordance with the Rules of Arbitration of the
International Chamber of Commerce in force on the date the demand for arbitration is filed, which
Rules are deemed to be incorporated by reference into this clause. The demand for arbitration may
be filed by either Party within a reasonable time after the executive mediation in accordance with
Section 14.5.1 has concluded, but no later than after the date upon which institution of legal
proceedings shall be barred by the applicable statute of limitations. There shall be three (3)
arbitrators. Each Party shall designate one arbitrator and the two party-designated arbitrators
shall select the third. In the event of the any one or more of the three (3) arbitrators has not
been selected by the thirtieth (30th) day following the date of the demand for arbitration, then
such arbitrator shall be selected in accordance with the aforesaid Rules. The language to be used
in the arbitral proceedings shall be English. The place of arbitration shall be San Francisco,
California, USA in the event InterMune is the defendant and Vienna, Austria in the event BI Austria
is the defendant. Any determination by such arbitration shall be final and conclusively binding.
Judgment on the arbitral award may be entered in any court having jurisdiction thereof. In the
event of arbitration, the costs of the arbitration shall be fixed in accordance with Article 31 of
the Rules of Arbitration of the International Chamber of Commerce and the final award will have the
Parties bearing the costs of arbitration in proportion to the outcome of the arbitration. If
applicable under the applicable law, the Parties will submit a proposed discovery schedule to the
arbitrator(s) at the pre-hearing conference. The scope and duration of discovery shall be
reasonably determined by the arbitrators.

     14.5.3 This AGREEMENT shall be governed by and construed in accordance with the laws of the
place of domicile of the defendant party.

     14.5.4 The Parties expressly exclude the application of the United Nations Convention on
Contracts for the International Sale of Goods to this AGREEMENT.

14.6 Independent Contractor

     Each of the Parties hereto is an independent contractor and nothing herein contained shall be
deemed to constitute the relationship of partners, joint venture, nor of principal and agent
between the Parties hereto. Neither Party shall have the authority to bind the other Party.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

32

 

14.7 Waiver

     Any delay in enforcing a Party’s rights under this AGREEMENT or any waiver as to a particular
default or other matter shall not constitute a waiver of such Party’s rights to the future
enforcement of its rights under this AGREEMENT, excepting only as to an express written and signed
waiver as to a particular matter for a particular period of time.

14.8 Severability

     If any of the provisions of this AGREEMENT or parts thereof should be or become invalid, the
remaining provisions will not be affected. The Parties shall undertake to replace the invalid
provision or parts thereof by a new provision which will approximate as closely as possible the
intent of the Parties.

14.9 Entire Agreement

     This AGREEMENT, the QUALITY AGREEMENT, the TERMINATION AGREEMENT and the Exhibits set forth
the entire agreement between the Parties, and supersede all previous agreements, negotiation and
understanding, written or oral, regarding the subject matter hereof. This AGREEMENT may be modified
or amended only by an instrument in writing duly executed on behalf of the Parties. For the
avoidance of doubt, this AGREEMENT does not supersede the TERMINATION AGREEMENT entered into by the
Parties on June 6, 2007.

14.10 Headings

     The section headings appearing herein are included solely for convenience of reference and are
not intended to affect the interpretation of any provision of this AGREEMENT.

14.11 Ambiguities

     Ambiguities, if any, in this AGREEMENT shall not be strictly construed against either Party,
regardless of which Party is deemed to have drafted the provision at issue.

14.12 Counterparts

     The AGREEMENT may be executed in two or more counterparts, each of which shall be an original
and all of which shall constitute the same document.

14.13 English Language

     The English language will govern any interpretation of or dispute in connection with this
AGREEMENT.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

33

 

14.14 Effect on Termination Agreement

     Upon the full execution of this AGREEMENT by all the Parties, the Effective Date of this
AGREEMENT shall be deemed the “Termination Date” for purposes of the TERMINATION AGREEMENT.

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

34

 

     In Witness Whereof, the Parties hereto have caused this AGREEMENT to be executed by
their duly authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 
	Vienna, Austria	 	 	 	Brisbane, California
	 
	 	 	 	 	 	 	 	 
	BOEHRINGER INGELHEIM 

AUSTRIA GMBH	 	 	 	INTERMUNE, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Dipl. Vw. Frank Ternes
	 	 	 	By:
	 	/s/ Robin Steele
	 

	 	 
	 	 	 	 	 	 
	Name:

	 	Dipl. Vw. Frank Ternes
	 	 	 	Name:
	 	Robin Steele
	 
	Title:

	 	Senior Vice President,

Division Biopharmaceuticals & Operations
	 	 	 	Title:
	 	Senior Vice President, General Counsel
	 
	 	 	 	 	 	 	 	 
	Date:

	 	29 June 2007
	 	 	 	Date:
	 	29 June 2007
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Prof. Dr. Rolf G. Werner	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Name:

	 	Prof. Dr. Rolf G. Werner	 	 	 	 	 	 
	 
	Title:

	 	Senior Vice President,	 	 	 	 	 	 
	 

	 	Corporate Division
Biopharmaceuticals	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date:

	 	29 June 2007	 	 	 	 	 	 

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

35

 

EXHIBIT 1

BBS SPECIFICATIONS

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 2

Certificate of Analysis (COA)

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 3

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 4

DNA sequence of INTERFERON GAMMA 1b

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 5

Manufacturing Process

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 6

Product

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 7

Project Manager and Project Team

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 8

Project Specification

[*]

 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

 

 

EXHIBIT 9

Steering Committee

[*]

 
 

			
	[*] = 	 	Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. Confidential treatment has been requested with
respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]